Litifilimab Sustains Skin Clearance Through 52 Weeks in Cutaneous Lupus
Litifilimab, an investigational type I interferon-targeting biologic, maintained durable skin clearance through 52 weeks in patients with cutaneous lupus erythematosus.
Topic
Cutaneous Lupus Erythematosus
Topic
Cutaneous Lupus Erythematosus
Enpatoran Phase 2 Trial Reports Symptom Improvement in Cutaneous Lupus
An oral TLR7/8 inhibitor met its Phase 2 primary endpoint in cutaneous lupus erythematosus, per a Dermatology Advisor report, tho…
Daxdilimab Cuts Disease Activity in Moderate-to-Severe Discoid Lupus
Phase 2 data show daxdilimab reduced disease activity in moderate-to-severe discoid lupus, a cutaneous lupus subtype with few tar…